Author

Camillo Almici

Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaORCID 0000-0002-9438-2569Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Adrian AndronacheiD· 1 shared Agnese SegalaiD· 1 shared Alessandra TucciiD· 1 shared Alessandra ValerioiD· 1 shared Andrea ZendriniiD· 1 shared Andrés J.M. FerreriiD· 1 shared Angelo MusicòiD· 1 shared Annalisa RadeghieriiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian AndronacheORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologyJournal of NanobiotechnologyPeer-reviewedJun 7, 2026

Red Blood Cell-derived Extracellular Vesicles enable Cisplatin and Cetuximab combined Therapy against Triple-Negative Breast Cancer

Miriam Romano, Angelo Musicò, Andrea Zendrini…·Annalisa Radeghieri

This paper develops a nanoplatform using red blood cell-derived extracellular vesicles to deliver Cetuximab and cisplatin, enhancing cancer cell killing and reducing toxicity in triple-negative breast cancer.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyBlood Cancer DiscoveryPeer-reviewedMay 22, 2025

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

Gabriele Varano, Silvia Lonardi, Paola Sindaco…·Stefano S Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

10 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky